CVS Health (NYSE:CVS) Price Target Raised to $114.00 at Argus

CVS Health (NYSE:CVS) had its price objective raised by investment analysts at Argus from $104.00 to $114.00 in a report released on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the pharmacy operator’s stock. Argus’ price objective would indicate a potential upside of 19.74% from the company’s previous close.

A number of other equities research analysts have also recently issued reports on the stock. Piper Sandler reiterated an “overweight” rating and issued a $113.00 price objective on shares of CVS Health in a report on Monday, June 1st. UBS Group boosted their price target on CVS Health from $122.00 to $126.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Morgan Stanley upped their price target on CVS Health from $106.00 to $111.00 and gave the stock an “overweight” rating in a research note on Thursday, June 4th. Bank of America raised their price objective on CVS Health from $100.00 to $110.00 and gave the company a “buy” rating in a research note on Monday, June 22nd. Finally, Wall Street Zen upgraded CVS Health from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 8th. Twenty-two equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $107.17.

CVS Health Trading Up 0.3%

Shares of NYSE CVS opened at $95.20 on Wednesday. The business has a 50 day simple moving average of $102.41 and a 200 day simple moving average of $88.56. CVS Health has a 52 week low of $69.51 and a 52 week high of $110.68. The stock has a market cap of $121.76 billion, a price-to-earnings ratio of 25.26, a PEG ratio of 0.93 and a beta of 0.61. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.66 and a current ratio of 0.87.

CVS Health (NYSE:CVS) last posted its earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.87 by $0.71. The firm had revenue of $106.10 billion during the quarter, compared to analysts’ expectations of $100.03 billion. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. The company’s revenue was up 7.3% compared to the same quarter last year. During the same period in the previous year, the company earned $1.81 earnings per share. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. On average, research analysts predict that CVS Health will post 8.02 earnings per share for the current fiscal year.

Insider Transactions at CVS Health

In other news, Director Larry Robbins sold 370,462 shares of the firm’s stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $93.45, for a total value of $34,619,673.90. Following the sale, the director directly owned 4,824,799 shares of the company’s stock, valued at approximately $450,877,466.55. This trade represents a 7.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.85% of the stock is owned by company insiders.

Institutional Trading of CVS Health

Several hedge funds have recently added to or reduced their stakes in CVS. Caitong International Asset Management Co. Ltd boosted its position in shares of CVS Health by 407.2% in the third quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock valued at $26,000 after acquiring an additional 281 shares during the period. Swiss RE Ltd. bought a new position in CVS Health during the fourth quarter worth $26,000. Kilter Group LLC acquired a new position in CVS Health during the 2nd quarter valued at $27,000. Sankala Group LLC bought a new stake in CVS Health in the 4th quarter valued at $28,000. Finally, Global Trust Asset Management LLC boosted its holdings in CVS Health by 344.8% in the 1st quarter. Global Trust Asset Management LLC now owns 387 shares of the pharmacy operator’s stock valued at $28,000 after purchasing an additional 300 shares during the period. Institutional investors own 80.66% of the company’s stock.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.